Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronary Restenosis Clear all
Completed Phase 2Phase 3 Interventional

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

NCT00055510
View directory record Official record
Conditions
Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions
BO-653
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 1:15 AM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 27, 2026, 1:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Radiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis

NCT00538759
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
External beam radiation therapy, Sham Control
Device · Other
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
75 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 27, 2026, 1:15 AM EDT
Recruiting No phase listed Observational

Abbott Vascular Medical Device Registry

NCT04573660
View directory record Official record
Conditions
Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism, Arterial Embolism
Interventions
Coronary and peripheral stents, Pacing catheters, Vascular plugs, Measurement and imaging (FFR and OCT), Peripheral dilatation catheters, Coronary dilatation catheters, Coronary and peripheral guidewires, Vessel closure/compression devices, Vascular access introducers
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

NCT00301522
View directory record Official record
Conditions
Coronary Stenosis
Interventions
TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2010 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional

STAR and Deferred Stenting Study

NCT05089864
View directory record Official record
Conditions
Coronary Occlusion, Coronary Stenosis, Coronary Restenosis
Interventions
Stent Placement Timing - Early, Stent Placement Timing - Late
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional Results available

Carotid Revascularization Endarterectomy Versus Stenting Trial

NCT00004732
View directory record Official record
Conditions
Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction, Myocardial Infarction
Interventions
Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
106
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 27, 2026, 1:15 AM EDT
Terminated Not applicable Interventional Results available

SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI

NCT03474432
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Optical Coherence Tomography, In-stent Coronary Artery Restenosis
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Jesse Brown VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional Results available

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

NCT01923740
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
XIENCE V EECSS, Absorb BVS System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Phase 3 Interventional

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

NCT00165035
View directory record Official record
Conditions
Coronary Disease
Interventions
CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 27, 2026, 1:15 AM EDT
Recruiting Not applicable Interventional

Prevail Global Study

NCT06535854
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prevail DCB, Agent DCB
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
55
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional Results available

A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon

NCT04985773
View directory record Official record
Conditions
Coronary Stenosis, Coronary Artery Stenosis, In-stent Restenosis
Interventions
Lacrosse NSE ALPHA coronary dilatation catheter
Device
Lead sponsor
Infraredx
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Palo Alto, California • Lexington, Kentucky • Maplewood, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 27, 2026, 1:15 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional

The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions

NCT00217269
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Stenting
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional

In Stent ELUTES Study

NCT00225680
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
drug eluting coronary stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 27, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional

Serp-1 for the Treatment of Acute Coronary Syndrome

NCT00243308
View directory record Official record
Conditions
Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
Interventions
Serine proteinase-1 (Serp-1)
Drug
Lead sponsor
Viron Therapeutics Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 27, 2026, 1:15 AM EDT
Withdrawn No phase listed Observational

REWARDS- In-stent Restenosis

NCT03008772
View directory record Official record
Conditions
In-Stent Coronary Artery Restenosis
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional

V-Flex Plus PTX Drug Eluting Coronary Stent

NCT00225693
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
drug eluting coronary stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Phase 4 Interventional

Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions

NCT00911976
View directory record Official record
Conditions
Coronary Artery Bypass, Atherosclerosis
Interventions
Xience V coronary stent
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 27, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT PRIME Clinical Trial

NCT00916370
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Core size Xience Prime, Xience Prime Long Lesion (LL)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
56
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sacramento, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 27, 2026, 1:15 AM EDT